疏肝和胃散治疗胆汁反流性胃炎的临床研究

《疏肝和胃散治疗胆汁反流性胃炎的临床研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、提要目的:观察中药方疏肝和胃散治疗胆汁反流性胃炎(BRG)的临床疗效。方法：采用随机对照法，将符合纳入标准的病例60例随机分为治疗组和对照组，治疗组30例，对照组30例。治疗组服用疏肝和胃散煎剂，对照组服用胆胃康胶囊。疗程:4周为l疗程，均于治疗前及服药1个疗程后进行疗效比较。结果:治疗后两组总体疗效及主要症状、体征疗效比较，治疗组均明显优于对照组（P＜0.01或P＜0.05)。在改善胆汁反流及胃粘膜炎症等方面，治疗组优于对照组（P＜0.05）。结论：疏肝和胃散对胆汁反流性胃炎的临床疗效好，未见毒副作用。其治疗机理可能是通过促进胃排空、协调胃及十二指肠运动

2、，抗炎、抗溃疡、保护胃粘膜等作用实现的。研究结果从临床角度验证了疏肝和胃散治疗胆汁反流性胃炎的实用性和可行性，且有进一步研究和探讨的价值。关键词疏肝和胃散；胆汁反流性胃炎；临床研究ClinicalStudyonShuganheweisaninTreatingBileRefluxGastritisSpecia1ity:InternalmedicineoftraditionalChinesemedicineAuthor:YangguoxiangTutor:ProfessorLiuweimingAbstractObjective:Toobservetheclin

3、icalcurativeeffectofshuganheweisanintreatingbilerefluxgastritis(BRG).Methods:Therandomizedcontrolledmethodwasadopted.Theselectedcaseswererandomlydividedintotwogroups:treatmentgroupsandcontorlgroups.30patientsintreatmentgroupweretreatedwithShuganheweisan,andpatientsincontrolgroupwe

4、retreatedwithDanweikangCapsule.Treatment:Allpatientsweretreatedforfourweeks.Thechangesofprimaryclinicalsymptomsandsignsinallcaseswereobservedandgivenevaluationaftertreatment.Result:Thecurativeeffectofthetherapygroupwereobviouslybetterthanthatofthecontorlgroup(P＜0.01orP＜0.05).Concl

5、usions:ShuganheweisanisaeffectiveformulartocureBRG.Nosignificanttoxicandsideeffectandadversereactionsareobserved.Themechanismoftheformularisprobablytopromotegastritisemptying，harmonizestomach-duodenal,anti-gastritis,anti-ulcerandprotectthestomach.Thisfindingauthenticatedtheclinica

6、lutilityandfeasibilityofShuganheweisan.Thendeepstudyandapproacharedeserved.KeywordShuganheweisan;BileRefluxGastritis;Clinicalresearch目录引言...............................................................................................................................1临床研究............

7、...................................................................................................................2一、病例选择标准...............................................................................................................2（一）诊断标准......................................

8、.................................